Tectonic Therapeutic Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Alise Reicin
Chief executive officer
US$932.0k
Total compensation
| CEO salary percentage | 61.7% |
| CEO tenure | no data |
| CEO ownership | 2.0% |
| Management average tenure | 2.4yrs |
| Board average tenure | no data |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$53m |
| Jun 30 2024 | n/a | n/a | -US$46m |
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$932k | US$575k | -US$43m |
Compensation vs Market: Alise's total compensation ($USD931.96K) is below average for companies of similar size in the US market ($USD3.22M).
Compensation vs Earnings: Insufficient data to compare Alise's compensation with company performance.
CEO
Alise Reicin (63 yo)
no data
Tenure
US$931,962
Compensation
Dr. Alise S. Reicin, MD, PhD, serves as Member of Strategic Advisory Board at SCTbio a.s. (formerly known as Sotio a.s.). since November 2021. She serves on the board of directors of Sana Biotherapeutics a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$931.96k | 1.97% $ 14.7m | |
| Chief Medical Officer | 3.4yrs | US$699.78k | 0.22% $ 1.6m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Scientific Officer | 2.4yrs | no data | 0.096% $ 717.3k | |
| Senior Vice President of People & Culture | 2.4yrs | no data | no data | |
| Chief Development Officer | no data | no data | no data | |
| Chief Business Officer | no data | no data | 0.014% $ 101.1k | |
| Senior Vice President of Antibody Engineering & Protein Sciences | no data | no data | no data |
2.4yrs
Average Tenure
53yo
Average Age
Experienced Management: TECX's management team is considered experienced (2.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 06:04 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tectonic Therapeutic, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Risinger | Leerink Partners LLC |
| Yasmeen Rahimi | Piper Sandler Companies |
| Danielle Brill Bongero | Raymond James & Associates |